載入...
“Economic Evidence on Identifying Clinically Actionable Findings with Whole Genome Sequencing: A Scoping Review”
BACKGROUND: The American College of Medical Genetics (ACMG) recommends that mutations in 56 genes for 24 conditions are clinically actionable, and should be reported as secondary findings after whole genome sequencing (WGS). Our aim was to identify published economic evaluations of detecting mutatio...
Na minha lista:
| 發表在: | Genet Med |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4654986/ https://ncbi.nlm.nih.gov/pubmed/25996638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/gim.2015.69 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|